{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T17:52:33Z","timestamp":1726163553306},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.nucmedbio.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T15:03:02Z","timestamp":1248966182000},"page":"811-819","source":"Crossref","is-referenced-by-count":9,"title":["In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Bart","family":"Cornelissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Kersemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"McLarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Vallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib2","unstructured":"Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt) 2002;16:1340-8, 51-2. [discussion 52, 55-8]."},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/sonc.2002.32899","article-title":"c-erbB-2 in breast cancer: development of a clinically useful marker","volume":"29","author":"Hayes","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib4","first-page":"5078","article-title":"HER-2-targeted therapy: lessons learned and future directions","volume":"9","author":"Nahta","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Sciences (New York)"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdg483","article-title":"Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?","volume":"14","author":"Jones","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","article-title":"Molecular mechanisms underlying ErbB2\/HER2 action in breast cancer","volume":"19","author":"Harari","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib8","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","article-title":"HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/jnci\/93.24.1830","article-title":"Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect","volume":"93","author":"Albanell","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1524-4741.2003.09602.x","article-title":"Clinical experience with trastuzumab (Herceptin)","volume":"9","author":"Vogel","year":"2003","journal-title":"Breast J"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1128\/MCB.20.9.3210-3223.2000","article-title":"ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency","volume":"20","author":"Lane","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib13","first-page":"260","article-title":"Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms","volume":"6","author":"Le","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib14","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.20378","article-title":"Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells","volume":"112","author":"Marches","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib16","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1158\/0008-5472.CAN-03-3900","article-title":"P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nat Rev"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib18","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/0008-5472.CAN-04-2271","article-title":"Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1","volume":"65","author":"Jeon","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cbr.2007.0430","article-title":"Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications","volume":"23","author":"Costantini","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2174\/138161208785777432","article-title":"Cell penetrating peptides for in vivo molecular imaging applications","volume":"14","author":"Kersemans","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nucmedbio.2006.10.008","article-title":"Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells","volume":"34","author":"Cornelissen","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nucmedbio.2007.09.007","article-title":"Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection","volume":"35","author":"Cornelissen","year":"2008","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00259-005-1908-7","article-title":"Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer","volume":"33","author":"Hu","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00259-006-0189-0","article-title":"123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1\/Cip-1)","volume":"34","author":"Hu","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1021\/bc060053r","article-title":"HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1\/CIP-1","volume":"17","author":"Hu","year":"2006","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0006-291X(78)91322-0","article-title":"Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril","volume":"80","author":"Fraker","year":"1978","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s004280050408","article-title":"Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients","volume":"435","author":"Reed","year":"1999","journal-title":"Virchows Arch"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib28","first-page":"2848","article-title":"Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study","volume":"5","author":"Baekelandt","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib29","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2967\/jnumed.106.037937","article-title":"(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2\/neu-amplified breast cancer","volume":"48","author":"Costantini","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/MMBR.65.4.570-594.2001","article-title":"Transport into and out of the nucleus","volume":"65","author":"Macara","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib31","doi-asserted-by":"crossref","DOI":"10.1089\/cbr.2008.0553","article-title":"111In-Labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1","author":"Cornelissen","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib32","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.2174\/138161208786898842","article-title":"Peptide-based nanoparticle for ex vivo and in vivo drug delivery","volume":"14","author":"Crombez","year":"2008","journal-title":"Current Pharma Des"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbamem.2006.01.006","article-title":"Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly","volume":"1758","author":"Pujals","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.bjc.6603553","article-title":"Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms","volume":"96","author":"Legrier","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib35","series-title":"AACR Meeting Abstracts","first-page":"802","article-title":"ZD1839 (Iressa\u2122) sensitivity is regulated through a p27-dependent mechanism in bladder cancer cells","author":"Shrader","year":"2005"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1368-8375(03)00131-3","article-title":"Gefitinib (\u2018Iressa\u2019, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines","volume":"40","author":"Shintani","year":"2004","journal-title":"Oral oncology"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/eje.1.02213","article-title":"Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours","volume":"155","author":"Hubina","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nucmedbio.2009.05.003_bib38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1245\/ASO.2004.03.095","article-title":"Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome","volume":"11","author":"Moore","year":"2004","journal-title":"Ann Surg Oncol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805109001279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805109001279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T19:56:47Z","timestamp":1558468607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805109001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0969805109001279"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.05.003","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}